의인성 안구건조증에서 신경펩티드의 변화와 가능한 역할 = Changes and Possible Role of Neuropeptides in Iatrogenic Dry Eye

국문 초록 (Abstract)

최근 안구건조증의 발병기전에 각막신경의 역할이 부각되고 있다. 신경펩티드가 신경계와 면역계의 중요한 매개체로 알려져 있다는점을 고려하면, 신경 말단에서 분비되는 신경펩티드가 유발하고 조절하는 신경성염증은 안구건조증의 발병기전에도 관여할 것으로기대된다. 최근에 눈 수술 및 콘택트렌즈 사용 후에 발생하는 안구건조증에 대한 관심이 증가하면서, 의인성 안구건조증은 안구건조증의 중요한 분야로 각광을 받고 있다. 이 논문에서는 안구건조증의 발병기전과 관련하여 신경펩티드의 역할에 대한 최근 연구 결과들을 간단히 살펴보고, 특히 의인성 안구건조증에서 신경펩티드의 변화 및 가능한 역할에 대한 기존 연구 결과들을 정리하고자 한다.

참고문헌 (Reference)

1 The definition, "report of the definition and classification subcommittee of the international dry eye workshop(2007)" 5 : 75-92, 2007

2 Lasagni Vitar RM, "The two-faced effects of nerves and neuropeptides in corneal diseases" 86 : 100974-, 2022

3 Stern ME, "The role of the lacrimal functional unit in the pathophysiology of dry eye" 78 : 409-416, 2004

4 Hwang DD, "The role of neuropeptides in pathogenesis of dry dye" 10 : 4248-, 2021

5 Micera A, "The role of neuromediators in ocular allergy" 8 : 466-471, 2008

6 Markoulli M, "The relationship between corneal nerve morphology and inflammatory mediators and neuropeptides in healthy individuals" 97 : 145-153, 2020

7 Colorado LH, "The relationship between corneal dendritic cells, corneal nerve morphology and tear inflammatory mediators and neuropeptides in healthy individuals" 44 : 840-848, 2019

8 Sabatino F, "The intriguing role of neuropeptides at the ocular surface" 15 : 2-14, 2017

9 Alexander SP, "The concise guide to pharmacology. 2017/18: G protein-coupled receptors" 174 (174): S17-S129, 2017

10 Tummanapalli SS, "Tear film substance P : a potential biomarker for diabetic peripheral neuropathy" 17 : 690-698, 2019

11 Steinhoff MS, "Tachykinins and their receptors : contributions to physiological control and the mechanisms of disease" 94 : 265-301, 2014

12 Khawaja AM, "Tachykinins : receptor to effector" 28 : 721-738, 1996

13 Maggi CA, "Tachykinin receptors and tachykinin receptor antagonists" 13 : 23-93, 1993

14 Meseguer V, "TRPA1 channels mediate acute neurogenic inflammation and pain produced by bacterial endotoxins" 5 : 3125-, 2014

15 Bron AJ, "TFOS DEWS II pathophysiology report" 15 : 438-510, 2017

16 Gomes JAP, "TFOS DEWS II iatrogenic report" 15 : 511-538, 2017

17 López-de la Rosa A, "Substance P level in tears as a potential biomarker for contact lens discomfort" 29 : 43-56, 2021

18 Yang L, "Substance P inhibits hyperosmotic stress-induced apoptosis in corneal epithelial cells through the mechanism of Akt activation and reactive oxygen species scavenging via the neurokinin-1 receptor" 11 : e0149865-, 2016

19 Gong X, "Substance P induces sympathetic immune response in the contralateral eye after the first eye cataract surgery in type 2 diabetic patients" 20 : 339-, 2020

20 Yamada M, "Substance P and its metabolites in normal human tears" 43 : 2622-2625, 2002

21 Linder S, "Structure and expression of the gene encoding the vasoactive intestinal peptide precursor" 84 : 605-609, 1987

22 Chao C, "Structural and functional changes in corneal innervation after laser in situ keratomileusis and their relationship with dry eye" 253 : 2029-2039, 2015

23 Choi JE, "Skin neurogenic inflammation" 40 : 249-259, 2018

24 Gozes I, "Sequential expression in the nervous system of C-myb and VIP genes, located in human chromosomal region 6q24" 13 : 305-313, 1987

25 Liu L, "Sensory neurons directly promote angiogenesis in response to inflammation via substance P signaling" 34 : 6229-6243, 2020

26 Matsuda M, "Roles of inflammation, neurogenic inflammation, and neuroinflammation in pain" 33 : 131-139, 2019

27 Suvas S, "Role of substance P neuropeptide in inflammation, wound healing, and tissue homeostasis" 199 : 1543-1552, 2017

28 Taketani Y, "Restoration of regulatory T-cell function in dry eye eisease by antagonizing substance P/neurokinin-1 receptor" 190 : 1859-1866, 2020

29 Figueira L, "Regulation of corneal noradrenaline release and topography of sympathetic innervation : functional implications for adrenergic mechanisms in the human cornea" 174 : 121-132, 2018

30 Regoli D, "Receptors and antagonists for substance P and related peptides" 46 : 551-599, 1994

31 Solés-Tarrés I, "Protective effects of pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal peptide against cognitive eecline in neurodegenerative diseases" 14 : 221-, 2020

32 Harmar AJ, "Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide : IUPHAR review 1" 166 : 4-17, 2012

33 Konttinen YT, "Peptide-containing nerves in labial salivary glands in Sjögren's syndrome" 35 : 815-820, 1992

34 Byun YS, "Ocular surface inflammation induces de novo expression of substance P in the trigeminal primary afferents with large cell bodies" 10 : 15210-, 2020

35 Kulka M, "Neuropeptides activate human mast cell degranulation and chemokine production" 123 : 398-410, 2008

36 Mashaghi A, "Neuropeptide substance P and the immune response" 73 : 4249-4264, 2016

37 Tatemoto K, "Neuropeptide Y--a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide" 296 : 659-660, 1982

38 Pedragosa-Badia X, "Neuropeptide Y receptors: how to get subtype selectivity" 4 : 5-, 2013

39 Tatemoto K, "Neuropeptide Y : complete amino acid sequence of the brain peptide" 79 : 5485-5489, 1982

40 Gray TS, "Neuropeptide Y : anatomical distribution and possible function in mammalian nervous system" 38 : 389-401, 1986

41 Yu M, "Neurokinin-1 receptor antagonism ameliorates dry eye disease by inhibiting antigen-presenting cell maturation and T helper 17 cell activation" 190 : 125-133, 2020

42 Mantelli F, "Neurogenic inflammation of the ocular surface" 10 : 498-504, 2010

43 Littlejohn G, "Neurogenic inflammation in fibromyalgia" 40 : 291-300, 2018

44 Chiu IM, "Neurogenic inflammation and the peripheral nervous system in host defense and immunopathology" 15 : 1063-1067, 2012

45 Ramachandran R, "Neurogenic inflammation and its role in migraine" 40 : 301-314, 2018

46 Corrigan F, "Neurogenic inflammation after traumatic brain injury and its potentiation of classical inflammation" 13 : 264-, 2016

47 Beuerman RW, "Neurogenic inflammation : a first line of defense for the ocular surface" 3 : S203-S206, 2005

48 He J, "Neuroanatomy and neurochemistry of mouse cornea" 57 : 664-674, 2016

49 Hoşal BM, "Morphology of corneal nerves and corneal sensation in dry eye: a preliminary study" 19 : 1276-1279, 2005

50 Batbayar B, "Morphological basis of sensory neuropathy and neuroimmunomodulation in minor salivary glands of patients with Sjögren's syndrome" 49 : 529-538, 2004

51 Lasagni Vitar RM, "Modulating ocular surface pain through neurokinin-1 receptor blockade" 62 : 26-, 2021

52 Chao C, "Long-term effects of LASIK on corneal innervation and tear neuropeptides and the associations with dry eye" 32 : 518-524, 2016

53 Poyner DR, "International union of pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors" 54 : 233-246, 2002

54 Mertaniemi P, "Increased release of immunoreactive calcitonin gene-related peptide(CGRP)in tears after excimer laser keratectomy" 60 : 659-665, 1995

55 Erdélyi B, "In vivo confocal laser scanning microscopy of the cornea in dry eye" 245 : 39-44, 2007

56 Gerard NP, "Human substance P receptor(NK-1) : organization of the gene, chromosome localization, and functional expression of cDNA clones" 30 : 10640-10646, 1991

57 Steinman L, "Elaborate interactions between the immune and nervous systems" 5 : 575-581, 2004

58 Gao S, "Early changes in ocular surface and tear inflammatory mediators after small-incision lenticule extraction and femtosecond laser-assisted laser in situ keratomileusis" 9 : e107370-, 2014

59 Stevenson W, "Dry eye disease : an immunemediated ocular surface disorder" 130 : 90-100, 2012

60 Törnwall J, "Distribution of vasoactive intestinal peptide(VIP)and its binding sites in labial salivary glands in Sjögren's syndrome and in normal controls" 12 : 287-292, 1994

61 Hegarty DM, "Differential localization of vesicular glutamate transporters and peptides in corneal afferents to trigeminal nucleus caudalis" 518 : 3557-3569, 2010

62 Yamada M, "Decreased substance P concentrations in tears from patients with corneal hypesthesia" 129 : 671-672, 2000

63 Yang LWY, "Corneal neuromediator profiles following laser refractive surgery" 16 : 2177-2183, 2021

64 Al-Aqaba MA, "Corneal nerves in health and disease" 73 : 100762-, 2019

65 Müller LJ, "Corneal nerves : structure, contents and function" 76 : 521-542, 2003

66 Golebiowski B, "Corneal nerve morphology, sensitivity, and tear neuropeptides in contact lens wear" 94 : 534-542, 2017

67 Lee SJ, "Corneal lymphangiogenesis in dry eye disease is regulated by substance P/neurokinin-1 receptor system through controlling expression of vascular endothelial growth factor receptor 3" 22 : 72-79, 2021

68 Launay PS, "Combined 3DISCO clearing method, retrograde tracer and ultramicroscopy to map corneal neurons in a whole adult mouse trigeminal ganglion" 139 : 136-143, 2015

69 Russell FA, "Calcitonin gene-related peptide : physiology and pathophysiology" 94 : 1099-1142, 2014

70 Benítez del Castillo JM, "An in vivo confocal masked study on corneal epithelium and subbasal nerves in patients with dry eye" 45 : 3030-3035, 2004

71 Pflugfelder SC, "Altered cytokine balance in the tear fluid and conjunctiva of patients with Sjögren's syndrome keratoconjunctivitis sicca" 19 : 201-211, 1999

72 Lambiase A, "Alterations of tear neuromediators in dry eye disease" 129 : 981-986, 2011

73 Lim JE, "A neuropeptide, substance-P, directly induces tissue-repairing M2 like macrophages by activating the PI3K/Akt/mTOR pathway even in the presence of IFNγ" 7 : 9417-, 2017